EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTR‑targeting peptide [18F]SiTATE

R Ebner, A Lohse, M P Fabritius, J Rübenthaler, C Wängler, B Wängler, R Schirrmacher, F Völter, H P Schmid, L M Unterrainer, O Öcal, A Hinterberger und 7 weitere

European Radiology · 2024

DOI: 10.1007/s00330-024-10788-3 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift European Radiology, 2024. Verfasst von R Ebner und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany. ricarda.ebner@med.uni-muenchen.de. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Positron Emission Tomography Computed Tomography, Receptors, Somatostatin, Radiopharmaceuticals. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Somatostatin receptor positron emission tomography/computed tomography (SSTR-PET/CT) using [ 68 Ga]-labeled tracers is a widely used imaging modality for neuroendocrine tumors (NET). Recently, [ 18 F]SiTATE, a SiFAlin tagged [Tyr3]-octreotate (TATE) PET tracer, has shown great potential due to favorable clinical characteristics. We aimed to evaluate the reproducibility of Somatostatin Receptor-Reporting and Data System 1.0 (SSTR-RADS 1.0) for structured interpretation and treatment planning of NET using [ 18 F]SiTATE.

Methods

Four readers assessed [ 18 F]SiTATE-PET/CT of 95 patients according to the SSTR-RADS 1.0 criteria at two different time points. Each reader evaluated up to five target lesions per scan. The overall scan score and the decision on peptide receptor radionuclide therapy (PRRT) were considered. Inter- and intra-reader agreement was determined using the intraclass correlation coefficient (ICC).

Results

The ICC analysis on the inter-reader agreement using SSTR-RADS 1.0 for identical target lesions (ICC ≥ 85%), overall scan score (ICC ≥ 90%), and the decision to recommend PRRT (ICC ≥ 85%) showed excellent agreement. However, significant differences were observed in recommending PRRT among experienced readers (ER) ( p = 0.020) and inexperienced readers (IR) ( p = 0.004). Compartment-based analysis demonstrated good to excellent inter-reader agreement for most organs (ICC ≥ 74%), except for lymph nodes (ICC ≥ 53%).

Conclusion

SSTR-RADS 1.0 represents a highly reproducible and consistent framework system for stratifying SSTR-targeted PET/CT scans, even using the novel SSTR-ligand [ 18 F]SiTATE. Some inter-reader variability was observed regarding the evaluation of uptake intensity prior to PRRT as well as compartment scoring of lymph nodes, indicating that those categories require special attention during further clinical validation and might be refined in a future SSTR-RADS version 1.1. Clinical relevance statement SSTR-RADS 1.0 is a consistent framework for categorizing somatostatin receptor-targeted PET/CT scans when using [ 18 F]SiTATE. The framework serves as a valuable tool for facilitating and improving the management of patients with NET. Key Points SSTR-RADS 1.0 is a valuable tool for managing patients with NET . SSTR-RADS 1.0 categorizes patients with showing strong agreement across diverse reader expertise . As an alternative to [ 68 Ga]-labeled PET/CT in neuroendocrine tumor imaging, SSTR-RADS 1.0 reliably classifies [ 18 F]SiTATE-PET/CT .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPositron Emission Tomography Computed TomographyReceptors, SomatostatinRadiopharmaceuticalsHumansFemaleMaleMiddle AgedReproducibility of ResultsAgedAdultAged, 80 and overOctreotideFluorine Radioisotopes

Stichwörter der Autor:innen

Molecular imagingNeuroendocrine tumorsPositron emission tomography-computed tomographySomatostatin

Substanzen

Receptors, SomatostatinRadiopharmaceuticalsOctreotideFluorine Radioisotopes

Autor:innen und Institutionen

  • Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany. ricarda.ebner@med.uni-muenchen.de.
  • Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany.
  • Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM, ENETS certified Center of Excellence), LMU University Hospital, LMU Munich, Munich, Germany.
  • Biomedical Chemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany.
  • Molecular Imaging and Radiochemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany.
  • Department of Oncology, Division of Oncological Imaging, University of Alberta, Edmonton, Canada.

Zitieren

APA

Ebner, R., Lohse, A., Fabritius, M. P., Rübenthaler, J., Wängler, C., Wängler, B., Schirrmacher, R., Völter, F., Schmid, H. P., Unterrainer, L. M., Öcal, O., Hinterberger, A., Spitzweg, C., Auernhammer, C. J., Geyer, T., Ricke, J., Bartenstein, P., Holzgreve, A., & Grawe, F. (2024). Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTR‑targeting peptide [18F]SiTATE. European Radiology. https://doi.org/10.1007/s00330-024-10788-3

Vancouver

Ebner R, Lohse A, Fabritius MP, Rübenthaler J, Wängler C, Wängler B, et al. Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTR‑targeting peptide [18F]SiTATE. European Radiology. 2024. doi:10.1007/s00330-024-10788-3

BibTeX
@article{Ebner2024,
  author = {Ebner, R and Lohse, A and Fabritius, M P and Rübenthaler, J and Wängler, C and Wängler, B and Schirrmacher, R and Völter, F and Schmid, H P and Unterrainer, L M and Öcal, O and Hinterberger, A and Spitzweg, C and Auernhammer, C J and Geyer, T and Ricke, J and Bartenstein, P and Holzgreve, A and Grawe, F},
  title = {Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTR‑targeting peptide [18F]SiTATE},
  journal = {European Radiology},
  year = {2024},
  doi = {10.1007/s00330-024-10788-3}
}
Kostenlos starten →